View Document Preview and Link Document Date: 2014-05-22 07:41:26 Open Document File Size: 1,03 MB Share Result on Facebook
Company SVR24 / SVR12 / / Continent America / / Event FDA Phase / Business Partnership / / Facility VA facility / / IndustryTerm treatment of hepatitis C / treatment of HCV / HCV treatment / food / / MedicalCondition Infection VI / cancer / HIV / disease / HBV / HCV Genotype 1 / Virus (HCV) Infection / liver failure / hepatocellular carcinoma / membranoproliferative glomerulonephritis / Liver Diseases / chronic HCV / cirrhosis / significant extrahepatic disease / hepatic encephalopathy / hepatitis C / HCV / significant extra-hepatic disease / Liver fibrosis / pulmonary / Virus Infection / leukocytoclastic vasculitis / liver cancer / HCV Genotype 3 / infection / liver disease / HCV Genotype 2 / Infection IV / chronic hepatitis B / cryoglobulinemia / chronic hepatitis C / disorders / Autoimmune diseases / HCV Genotype / HCV RNA / determined fibrosis / / MedicalTreatment birth control / liver transplant / CCR / antiviral therapy / / Organization U.S. Department of Health and Human Services / Program Office / U.S. Food and Drug Administration / FDA / Department of Veterans Affairs / office of Public Health / / Position Governor / / Product ribavirin / peginterferon / 204671Orig1s000SumR / F0-2 / / Technology Genotype / / URL www.hepatitis.va.gov / www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204671Orig1s000SumR.pdf / www.hcvguidelines.org / www.hepatitis.va.gov/provider/guidelines/2012HCV-pretreatment-assessments.asp / / SocialTag 
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health (March 27, 2014; data last reviewed